GF CSI Innovative Drugs Industry ETF(515120) rises 2.28%, aiming for a third consecutive gain

NewTimeSpace (newtimespace.com) News, as of 10:05 on July 22, 2026, GF Innovative Drug ETF (515120) rose 2.28%, aiming for a third consecutive gain. The latest price was 0.67 yuan. Over a longer time frame, as of July 21, 2026, the ETF accumulated a gain of 5.79% over the past two weeks, ranking 2/7 among comparable funds.

In terms of liquidity, GF Innovative Drug ETF recorded an intraday turnover rate of 4.06% and a trading volume of 529 million yuan. Over a longer time frame, as of July 21, the ETF's average daily trading volume over the past week reached 1.530 billion yuan, ranking in the top 2 among comparable funds.

In terms of scale, the latest scale of GF Innovative Drug ETF reached 12.828 billion yuan, hitting a one-year high and ranking 2/7 among comparable funds. (Data source: Wind)

In terms of shares, the latest share count of GF Innovative Drug ETF reached 19.508 billion units, hitting a one-year high and ranking 2/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net inflow for GF Innovative Drug ETF was 150 million yuan. Over a longer time frame, within the past five trading days, there were three days of net inflow, attracting a total of 554 million yuan, with an average daily net inflow of 111 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. GF Innovative Drug ETF recorded a net margin financing purchase of 2.5852 million yuan month-to-date, with the latest margin financing balance standing at 435 million yuan. (Data source: Wind)

As of July 21, the net value of GF Innovative Drug ETF rose by 38.76% over the past two years. From the perspective of return capability, as of July 21, 2026, since its inception, the ETF achieved a highest single-month return of 23.00%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 32.68%, and an average return of 5.48% in up months. As of July 21, 2026, the ETF's annualized excess return over its benchmark for the past three months was 4.00%.

In terms of drawdown, as of July 21, 2026, GF Innovative Drug ETF recorded a drawdown of 0.14% relative to its benchmark over the past six months, reflecting lower drawdown risk among comparable funds. The number of days to recover after the drawdown was 36 days.

In terms of fees, GF Innovative Drug ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of July 21, 2026, the one-month tracking error of GF Innovative Drug ETF was 0.023%, achieving the highest tracking accuracy among comparable funds.

GF Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.